山东新华制药股份:收到国家药监局核准签发的阿仑膦酸钠口服溶液《药品注册证书》

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Alendronate Sodium Oral Solution, which is indicated for the treatment of osteoporosis in postmenopausal women and men, aimed at preventing hip and vertebral fractures [1] Company Summary - The newly approved Alendronate Sodium Oral Solution is designed to increase bone mass and prevent fractures in specific patient populations [1] - The projected sales revenue for Alendronate Sodium in 2024 across major distribution channels, including public hospitals, grassroots medical institutions, and retail pharmacies, is estimated to reach RMB 720 million [1]